

A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Published: 28-12-2020

Last updated: 14-12-2024

Primary Objective: To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo.

Ethical review	Approved WMO
Status	Completed
Health condition type	Skin and subcutaneous tissue disorders NEC
Study type	Interventional

Summary

ID

NL-OMON51116

Source

ToetsingOnline

Brief title

TRuE-V LTE Study

Condition

- Skin and subcutaneous tissue disorders NEC

Synonym

leucoderma, white patches of skin

Research involving

Human

Sponsors and support

Primary sponsor: Incyte Corporation

Source(s) of monetary or material Support: Incyte Corporation

Intervention

Keyword: Ruxolitinib, Vehicle-Controlled, Vitiligo

Outcome measures

Primary outcome

For participants who are randomized in Cohort A: * Time to relapse (defined as < F-VASI75)

Secondary outcome

For participants who are randomized in Cohort A: * Time to maintain * F-VASI90 response

and:

* Proportion of participants who achieve F-VASI50/75/90 during the extension treatment period.

* Actual measurements, change, and percentage change from baseline in F-VASI.

* Proportion of participants who achieve T-VASI50/75/90 during the extension treatment period.

* Actual measurements, change, and percentage change from baseline in T-VASI.

* Actual measurements, change, and percentage change from baseline in F-BSA.

* Actual measurements, change, and percentage change from baseline in T-BSA.

* Proportion of participants achieving a VNS of *4 * A lot less noticeable* or

*5 * No longer noticeable* during the extension treatment period

Study description

Background summary

Ruxolitinib cream is a topical formulation of ruxolitinib phosphate under development for the treatment of participants with AD, AA, plaque psoriasis, and vitiligo. Ruxolitinib phosphate is an inhibitor of the JAK family of protein TYKs. Inflammatory cytokines are strongly implicated in the pathogenesis of several dermatologic diseases. Because JAKs serve to translate extracellular signals from a number of relevant cytokines and growth factors upregulated in inflammatory diseases such as AD, AA, plaque psoriasis, and vitiligo, JAK inhibitors represent potential therapeutic agents for these disease states.

This is a Phase 3, double-blind, vehicle-controlled, randomized withdrawal and treatment extension study that will enroll eligible participants who have completed either Study INCB 18424-307, conducted at the AMC (NL70922.018.20)

Study objective

Primary Objective:

To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo.

Study design

Key Secondary Objective:

To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo

Other Secondary Objective:

To further evaluate the efficacy of ruxolitinib cream

Intervention

ruxolitinib cream 1.5% /:vehicle

Study burden and risks

Burden and risks: - Possible side effects from the treatment (side effects are described in Appendix D of the ICF) - Discomfort, soreness, bruising: in rare cases infection, light headedness/fainting from blood drawing - Rash or irritation from ECG sticky pads. - Commitment to follow instructions associated with the study treatment and visits schedule

Currently, there are no approved therapies for vitiligo, and treatments are

empirical and directed by the available clinical guidelines. Current therapies often do not lead to satisfactory response, and there are limitations and safety concerns with long-term use of some therapies, including topical or oral corticosteroids and calcineurin inhibitors. Given the psychosocial burden and stigma that has been reported in this disease, patients with vitiligo warrant access to new studies.

Contacts

Public

Incyte Corporation

Augustine Cut-Of 1891
Wilmington 19803
US

Scientific

Incyte Corporation

Augustine Cut-Of 1891
Wilmington 19803
US

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years)
Adolescents (16-17 years)
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

1. Currently enrolled and receiving treatment in INCB 18424-306 or INCB 18424-307 studies evaluating ruxolitinib cream in participants with vitiligo.

2. Currently tolerating ruxolitinib cream in the parent study and no safety concerns per investigators judgment.
3. Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements

Exclusion criteria

1. Has been permanently discontinued from study treatment in the parent study for any reason.
2. Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
3. Pregnant or breastfeeding woman

Study design

Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Completed
Start date (anticipated):	06-09-2021
Enrollment:	10
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	RUXOLITINIB CREAM

Generic name: INCB018424 PHOSPHATE CREAM

Ethics review

Approved WMO	
Date:	28-12-2020
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	29-03-2021
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	10-11-2021
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	14-03-2022
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2020-000987-53-NL

Register

CCMO

ID

NL75444.018.20